Intravitreal bevacizumab for subfoveal idiopathic choroidal neovascularization.

Objectives: To evaluate the short-term visual and anatomical outcomes and safety of intravitreal bevacizumab in subfoveal idiopathic choroidal neovascularization.

Methods: Thirty-two eyes of 32 patients with idiopathic choroidal neovascularization received intravitreal bevacizumab (1.25 mg/0.